Side Effects From Certain Immunotherapies May Be Higher Than Initially Reported

November 13, 2018 – An analysis of nearly 2,800 people with non-small cell lung cancer (NSCLC) who received the immune checkpoint inhibitors nivolumab, pembrolizumab, or atezolizumab found that unexpected medical problems, known as adverse events, may be more common than reported in the initial trials that led to the approval of these therapies. These findings will be presented at the upcoming 2018 Palliative and Supportive Care in Oncology Symposium … (leggi tutto)